Navigation Links
Novelos Therapeutics Prices $5.9 Million Public Offering
Date:12/1/2011

MADISON, Wis., Dec. 1, 2011 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCBB: NVLT), a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced the pricing of an underwritten public offering of 9,840,000 units at $0.60 per unit for gross proceeds of $5,904,000.  Each unit consists of one share of common stock and a warrant to purchase one share of common stock.  The warrants will have an exercise price of $0.60 per share and a 5-year term.  The Company has granted the underwriter a 45-day option to purchase up to an additional 15% of the units offered in the public offering to cover over-allotments, if any.  The offering is being made pursuant to an effective registration statement under the Securities Act of 1933, as amended.

Rodman & Renshaw, LLC, a wholly owned subsidiary of Rodman & Renshaw Capital Group, Inc. (NasdaqGM: RODM), is acting as sole underwriter for the offering.  Novelos expects to close the transaction, subject to customary conditions, on or about December 6, 2011.

This announcement shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer or sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.  The offering will be made only by means of a prospectus supplement and accompanying prospectus, copies of which may be obtained from Rodman & Renshaw, LLC, Prospectus Department, 1251 Avenue of the Americas, New York, NY, 10020, telephone: 212-356-0500 or email: placements@rodm.com.  Before any investment, an investor should read the prospectus supplement and the accompanying prospectus, including the information incorporated by reference therein, for more complete information about Novelos and this offe
'/>"/>

SOURCE Novelos Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Novelos Therapeutics Announces Dismissal of Putative Federal Securities Class Action Lawsuit
2. Novelos Therapeutics to Present at the 5th Lippert/Heilshorn Life Sciences & Medical Technologies Virtual Conference on June 16
3. Nonconformity of NOV002 Used in Phase 3 NSCLC Trial Sponsored by Novelos Therapeutics, Inc to NOV002 (Glutoxim(R)), Used in Phase 1/2 NSCLC and all Previous Trials
4. Unigenes Proprietary Peptelligence™ Platform Used to Commence Cara Therapeutics Phase 1 Clinical Trial of Oral Novel Peripherally-Acting Kappa Opioid Agonist
5. Antiviral Therapeutics - Technologies, Markets and Companies
6. Pain Management Therapeutics Market to 2017 - Price Competition to Intensify Following Patent Expiries of Lyrica and Cymbalta
7. Cara Therapeutics Initiates Phase I Study with Oral Formulation of Novel Peripherally-Acting Kappa Opioid Agonist
8. Amsterdam Molecular Therapeutics Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy
9. Prime Therapeutics Launches Retail Medication Therapy Management Program
10. Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference
11. TetraLogic Pharmaceuticals Announces Presentation of Data on Smac Mimetic TL32711 at AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... N.J. , July 29, 2014 Regado ... company focused on the Phase 3 clinical development of ... controllable antithrombotic drug system, today announced that it will ... Tuesday, Aug. 12, 2014, at 8:30 a.m. EDT to ... highlights. Interested participants and investors may access ...
(Date:7/29/2014)... July 29, 2014  Landauer, Inc. (NYSE: ... radiation measurement and monitoring, outsourced medical physics services and ... for the fiscal third quarter 2014 after the market ... The Company will host a conference call for investors ... Time (10 a.m. Eastern Time). Investors may access the ...
(Date:7/29/2014)... -- New high priced hepatitis C drugs will increase ... $2.9 to $5.8 billion next year, according to a ... by the Pharmaceutical Care Management Association (PCMA). Milliman projects ... much as 8.6 percent in 2015 as a result ... The study finds that the majority of ...
Breaking Medicine Technology:Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 2Regado Biosciences to Provide Second Quarter 2014 Financial Results and Corporate Highlights 3Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2014 Results 2New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2
... , SAN CLEMENTE, Calif., Nov. 17 Three ... ages of two through 12 are extremely, very, or ... according to a survey conducted by Opinion Research Corporation ... research of natural remedies including Sinupret® for Kids, a ...
... , DURHAM, N.C., Nov. 17 Oxygen Biotherapeutics, Inc. ... has begun shipping Dermacyte(TM) Oxygen Concentrate Gel to customers ... which are going out today, cover orders received through ... for our company - actually shipping a product to ...
Cached Medicine Technology:Survey Finds Mothers Take Children's Health Into Their Own Hands 2Survey Finds Mothers Take Children's Health Into Their Own Hands 3Survey Finds Mothers Take Children's Health Into Their Own Hands 4Oxygen Biotherapeutics, Inc. Begins Shipping Cosmetic Product to Customers 2
(Date:7/30/2014)... 2014 Regents Health Resources, a consulting ... brought health care industry veteran Daryl Demonbreun and former ... lead the company’s ambitious plans to grow into a ... been moving along at a steady pace for nearly ... a notch,” says Bob Maier, founder and chief executive ...
(Date:7/29/2014)... 30, 2014 Recently, iFitDress.com, a well-known wedding ... satin bridal gowns . Aside from this, it has ... up to 68 percent off. All of its old and ... The company’s sales representative says excitedly, “We are pleased to ... new range, there are a lot of amazing items. It ...
(Date:7/29/2014)... Dublin, Ireland (PRWEB) July 30, 2014 ... announced the successful completion of a Phase I trial ... Acid (DGLA). , This study was a randomized, placebo-controlled, ... to assess the safety, pharmacokinetics and effect of food ... confirmed the benign safety profile of DGLA following both ...
(Date:7/29/2014)... Johns Hopkins researchers say they have discovered a chemical ... reactions that, if confirmed in larger studies, could give ... person,s risk of attempting suicide. , The discovery, described ... suggests that changes in a gene involved in the ... a significant role in turning what might otherwise be ...
(Date:7/29/2014)... July 29, 2014 Daily Gossip reveals in ... this program claims that he cured his condition with the ... to share part of his experience. , He claimed ... and naturally in just 4 days. Since his method turned ... sufferers from all around the world. , The Nasal ...
Breaking Medicine News(10 mins):Health News:Sferrella and Demonbreun Join Regents Health Resources 2Health News:Cheap Satin Bridal Gowns Recently Provided By Well-known Supplier iFitDress.com 2Health News:DS107G-01 – Successful Completion of Phase I Oral DGLA Clinical Trial 2Health News:A blood test for suicide? 2Health News:A blood test for suicide? 3Health News:Nasal Polyps Treatment Miracle Review Reveals How to Cure Nasal Polyps Without Surgery 2
... HealthDay Reporter , FRIDAY, May 13 (HealthDay News) -- ... to a veterinary clinic near her home in Austin, Texas, when ... like herself," recalled Wong. After running a blood and ... Diabetes is on the rise as America,s cats and dogs grow ...
... in the brains of patients with Alzheimer disease collude, resulting ... cells, according to new findings published online in Neurobiology ... pathological forms of two proteins, amyloid beta and tau, which ... patients plaques and tangles may work in tandem ...
... News) -- Being well-informed about their disease may lead to ... and other emotions about their condition, according to new research. ... were taking medication to manage the disease, and had symptoms ... and abdomen. The women,s coping styles affected their levels ...
... By Dennis Thompson HealthDay Reporter , FRIDAY, May ... the punch line of jokes, prompting chuckles about "mystery meat" ... days, with childhood obesity reaching epidemic proportions in the United ... their kids fit and healthy through proper nutrition. "Five ...
... It,s something we just accept: the fact that the older we ... can leave our ,cars in the same parking lot each morning, ... day, it,s a challenge eight hours later to ,recall whether we ... can ,be introduced to new colleagues at a meeting and will ...
... May 12 (HealthDay News) -- Representatives for veteran TV ... a facility for surgery to remove a meningioma -- ... on the meninges, the brain,s protective outer membrane. ... monitoring this for years, and a neurosurgeon, Mary decided ...
Cached Medicine News:Health News:Fat Cats, Dogs Developing Diabetes, Report Finds 2Health News:Fat Cats, Dogs Developing Diabetes, Report Finds 3Health News:2 defective proteins conspire to impair the nerve cell's 'powerhouse' in Alzheimer's disease 2Health News:2 defective proteins conspire to impair the nerve cell's 'powerhouse' in Alzheimer's disease 3Health News:For Some Women, Knowing About Heart Failure Spurs Worry 2Health News:U.S. Pushes School Cafeterias Toward Healthier Offerings 2Health News:U.S. Pushes School Cafeterias Toward Healthier Offerings 3Health News:As time goes by, it gets tougher to 'just remember this' 2Health News:As time goes by, it gets tougher to 'just remember this' 3Health News:Brain Surgery for Mary Tyler Moore to Remove Benign Tumor 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: